About Us
Invion
Management Team
Board of Directors
Corporate Governance
Development
Photosoft™
INV102 (nadolol)
INV104 (zafirlukast)
Investors
Annual Reports
Financial Reports
Investor Presentations
Analyst Coverage
News & Media
Market Announcements
Investor and Media Contact
Contact
ASX:IVX
Home
›
ASX Releases
›
Appendix 4C
Appendix 4C
Posted on
January 28, 2016
by
Company Secretary
‹
Appendix 3B and Cleansing Notice
Changes to Board Structure
›
Posted in
ASX Releases
Latest Releases
Invion spin-off Chronic Airway Therapeutics selects leading CRO for the future development of nadolol
New formulation of Photosoft therapy shows increased effect in ovarian cancer
Photosoft granted patent protection in Australia
Demerger of respiratory assets – clarification on eligible shareholders
Invion to spinout respiratory assets and advance clinical development in China
News & Media Archive
September 2018
August 2018
July 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
August 2017
July 2017
April 2017
February 2017
January 2017
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
News & Media
Analyst Coverage
Annual Review
ASX Releases
Financial Reports
Presentations
